CymitQuimica logo

2-(Bis(2-chloroethyl)amino)-4-hydroxy-1,3,2-oxazaphosphinane 2-oxide

CAS:

Ref. 3D-FB175219

ne
Discontinued
10mg
Discontinued
25mg
Discontinued
50mg
Discontinued
100mg
Discontinued

Discontinued product. For inquiries about similar products, please fill out our form or email us at .

2-(Bis(2-chloroethyl)amino)-4-hydroxy-1,3,2-oxazaphosphinane 2-oxide
Biosynth

    Product Information

    Name:2-(Bis(2-chloroethyl)amino)-4-hydroxy-1,3,2-oxazaphosphinane 2-oxide
    Brand:Biosynth
    Description:This compound is a phosphoramidate analog of cyclophosphamide. It has been shown to have an effect on the glomerular filtration rate and to inhibit DNA, RNA, and protein synthesis in human cells. The compound binds to the dinucleotide phosphate (NDP) site of the enzyme polymerase chain reaction (PCR) with high affinity, and inhibits DNA synthesis by competing with ATP. This active form is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. The kinetics of this drug have been studied using a concentration-time curve on human serum samples. The matrix effect can be avoided by preparing samples for analysis in a liquid phase instead of a solid phase. The analytical method for this drug has been developed in heart tissue preparations from rats treated with this drug at
    Notice:Our products are intended for lab use only. For any other use, please contact us.

    Chemical properties

    Purity:Min. 95%

    Inquiry about discontinued product: 2-(Bis(2-chloroethyl)amino)-4-hydroxy-1,3,2-oxazaphosphinane 2-oxide

    ◻️
    CYMIT QUÍMICA, S.L. as responsible for the treatment will treat your data in order to respond to your queries or requests. You can access, rectify and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Web Privacy Policy.
    * Mandatory fields.